Suppr超能文献

Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

作者信息

Thura Min, Al-Aidaroos Abdul Qader, Gupta Abhishek, Chee Cheng Ean, Lee Soo Chin, Hui Kam Man, Li Jie, Guan Yeoh Khay, Yong Wei Peng, So Jimmy, Chng Wee Joo, Ng Chin Hin, Zhou Jianbiao, Wang Ling Zhi, Yuen John Shyi Peng, Ho Henry Sun Sien, Yi Sim Mei, Chiong Edmund, Choo Su Pin, Ngeow Joanne, Ng Matthew Chau Hsien, Chua Clarinda, Yeo Eugene Shen Ann, Tan Iain Bee Huat, Sng Joel Xuan En, Tan Nicholas Yan Zhi, Thiery Jean Paul, Goh Boon Cher, Zeng Qi

机构信息

Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, 138673, Singapore.

Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, 119082, Singapore.

出版信息

Nat Commun. 2021 Nov 2;12(1):6431. doi: 10.1038/s41467-021-26548-6.

DOI:10.1038/s41467-021-26548-6
PMID:34728638
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8564534/
Abstract
摘要

相似文献

1
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.作者更正：PRL3-单抗作为一种免疫疗法用于抑制表达PRL3癌蛋白的肿瘤。
Nat Commun. 2021 Nov 2;12(1):6431. doi: 10.1038/s41467-021-26548-6.
2
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.PRL3-单抗作为一种免疫疗法，抑制表达 PRL3 癌蛋白的肿瘤。
Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x.
3
Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.利用PRL3在儿童实体瘤中的频繁且特异性表达，使PRL3-人源化抗体首次用于儿童。
Mol Ther Oncolytics. 2023 Aug 18;30:153-166. doi: 10.1016/j.omto.2023.08.006. eCollection 2023 Sep 21.
4
PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse.PRL3 诱导多态性巨癌细胞被 PRL3-zumab 消除，以降低肿瘤复发率。
Commun Biol. 2021 Jul 29;4(1):923. doi: 10.1038/s42003-021-02449-8.
5
PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types.PRL3 作为多种癌症新型癌症免疫疗法的治疗靶点。
Theranostics. 2023 Mar 21;13(6):1876-1891. doi: 10.7150/thno.79265. eCollection 2023.
6
Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse.作者更正：PRL3诱导多倍体巨癌细胞，被PRL3单克隆抗体清除以减少肿瘤复发。
Commun Biol. 2021 Nov 8;4(1):1282. doi: 10.1038/s42003-021-02812-9.
7
PRL3-zumab, a first-in-class humanized antibody for cancer therapy.PRL3-单抗，一种用于癌症治疗的首创人源化抗体。
JCI Insight. 2016 Jun 16;1(9):e87607. doi: 10.1172/jci.insight.87607.
8
PRL‑3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients.PRL-3 在体外增加前列腺癌细胞的侵袭表型，其表达与患者的高级别前列腺肿瘤相关。
Int J Oncol. 2018 Feb;52(2):402-412. doi: 10.3892/ijo.2017.4208. Epub 2017 Nov 20.
9
PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation.泌乳素瘤蛋白3（PRL3）通过下调Csk导致Src激活，从而促进细胞侵袭和增殖。
J Biol Chem. 2007 Feb 23;282(8):5413-9. doi: 10.1074/jbc.M608940200. Epub 2006 Dec 27.
10
Phosphatase of regenerating liver 3 (PRL3) provokes a tyrosine phosphoproteome to drive prometastatic signal transduction.肝再生磷酸酶 3（PRL3）引发酪氨酸磷酸化蛋白质组以驱动促转移信号转导。
Mol Cell Proteomics. 2013 Dec;12(12):3759-77. doi: 10.1074/mcp.M113.028886. Epub 2013 Sep 12.

引用本文的文献

1
Suppression of Ovarian Cancer Cell Proliferation Is Associated with Upregulation of Cell-Matrix Adhesion Programs and Integrin-β4-Induced Cell Protection from Cisplatin.卵巢癌细胞增殖的抑制与细胞-基质黏附程序的上调以及整合素β4诱导的细胞对顺铂的保护作用相关。
Cancers (Basel). 2025 Apr 27;17(9):1472. doi: 10.3390/cancers17091472.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验